ArticleBiomedical reports2026
Protective effects of
Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging-related cognitive decline is closely associated with oxidative stress, cholinergic dysfunction and hippocampal vulnerability. Perilla seed oil (PSO), a functional food rich in α-linolenic acid and antioxidant phytochemicals, may have cognitive benefits; however, its efficacy and underlying mechanisms in experimental models of accelerated aging remain insufficiently understood. The present study aimed to investigate the effects of PSO supplementation on cognitive performance and neurobiological alterations in a D-galactose (D-Gal)-induced accelerated aging model in rats. Wistar rats were injected subcutaneously with D-Gal (300 mg/kg) daily for 8 weeks and simultaneously treated orally with PSO (100 or 500 mg/kg), fish oil (500 mg/kg) or vehicle. Cognitive function was evaluated using the Morris water maze and novel object recognition tests. Oxidative stress markers, including malondialdehyde (MDA), reduced glutathione (GSH) and superoxide dismutase (SOD), as well as acetylcholinesterase (AChE) activity, were assessed in the hippocampus. Neuronal cell density in the CA1 and CA3 regions was examined using Nissl staining. PSO supplementation significantly improved spatial memory performance and recognition memory, increased hippocampal SOD activity and reduced AChE activity compared with the D-Gal group. Although MDA and GSH levels did not differ significantly, both exhibited a tendency toward normalization. In addition, neuronal density in the CA3 region was significantly reduced in the D-Gal group compared with the control group, whereas no significant differences were observed in the CA1 region. These findings suggest that PSO attenuates D-Gal-induced cognitive impairment, which may be partially associated with enhanced antioxidant enzyme activity and modulation of cholinergic function, rather than with restoration of neuronal density. PSO may therefore represent a potential nutritional intervention for supporting cognitive function during aging-related neurobiological changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.